E Björnsson1, E Kalaitzakis, V Av Klinteberg, N Alem, R Olsson. 1. Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden. einar.bjornsson@medic.gu.se
Abstract
AIM: To evaluate the long-term prognosis of patients diagnosed with drug-induced liver injury, and the nature of the liver injury. METHODS: Patients with a diagnosis of drug-induced liver injury between 1994 and 2005 were identified in a university hospital clinic. Patients surviving drug-induced liver injury-associated liver failure were excluded. RESULTS: Seventy-seven cases were identified and those who were alive (69) were invited to attend follow-up. Of those patients who had died, none had died of liver disease. Of those patients who had survived, 59 were reviewed in the clinic. Patients had a median follow-up of 48 months. Before the diagnosis of drug-induced liver injury, nine had a chronic liver disease, four with autoimmune hepatitis, two with non-alcoholic liver disease, one each with non-alcoholic fatty liver disease, primary biliary cirrhosis and primary sclerosing cholangitis. There was no evidence of progression of their liver disease during follow-up. Among 50 patients without a known liver disease prior to the drug-induced liver injury, 10 had abnormal liver tests. Diagnostic work-up revealed alternative cause of liver disease in all except three patients (6%), who had asymptomatic abnormal liver tests (but normal bilirubin in all). CONCLUSIONS: Chronic abnormalities in liver tests, not explained by an identified liver disease, are very rare in patients previously diagnosed with drug-induced liver injury. This group of patients did not seem to have a clinically significant liver injury at long-term follow-up.
AIM: To evaluate the long-term prognosis of patients diagnosed with drug-induced liver injury, and the nature of the liver injury. METHODS:Patients with a diagnosis of drug-induced liver injury between 1994 and 2005 were identified in a university hospital clinic. Patients surviving drug-induced liver injury-associated liver failure were excluded. RESULTS: Seventy-seven cases were identified and those who were alive (69) were invited to attend follow-up. Of those patients who had died, none had died of liver disease. Of those patients who had survived, 59 were reviewed in the clinic. Patients had a median follow-up of 48 months. Before the diagnosis of drug-induced liver injury, nine had a chronic liver disease, four with autoimmune hepatitis, two with non-alcoholic liver disease, one each with non-alcoholic fatty liver disease, primary biliary cirrhosis and primary sclerosing cholangitis. There was no evidence of progression of their liver disease during follow-up. Among 50 patients without a known liver disease prior to the drug-induced liver injury, 10 had abnormal liver tests. Diagnostic work-up revealed alternative cause of liver disease in all except three patients (6%), who had asymptomatic abnormal liver tests (but normal bilirubin in all). CONCLUSIONS:Chronic abnormalities in liver tests, not explained by an identified liver disease, are very rare in patients previously diagnosed with drug-induced liver injury. This group of patients did not seem to have a clinically significant liver injury at long-term follow-up.
Authors: Robert J Fontana; Paul H Hayashi; Jiezhun Gu; K Rajender Reddy; Huiman Barnhart; Paul B Watkins; Jose Serrano; William M Lee; Naga Chalasani; Andrew Stolz; Timothy Davern; Jayant A Talwakar Journal: Gastroenterology Date: 2014-03-27 Impact factor: 22.682
Authors: James Rochon; Petr Protiva; Leonard B Seeff; Robert J Fontana; Suthat Liangpunsakul; Paul B Watkins; Timothy Davern; John G McHutchison Journal: Hepatology Date: 2008-10 Impact factor: 17.425
Authors: Robert J Fontana; Paul H Hayashi; Huiman Barnhart; David E Kleiner; K Rajender Reddy; Naga Chalasani; William M Lee; Andrew Stolz; Thomas Phillips; Jose Serrano; Paul B Watkins Journal: Am J Gastroenterol Date: 2015-09-08 Impact factor: 10.864
Authors: Paula Iruzubieta; Maria Teresa Arias-Loste; Lucía Barbier-Torres; Maria Luz Martinez-Chantar; Javier Crespo Journal: Biomed Res Int Date: 2015-12-28 Impact factor: 3.411